Olmesartan/Amlodipin/Hydrochlorothiazid Glenmark (Olmesartan Medoxomil, Amlodipine, Hydrochlorothiazide)

Olmesartan/Amlodipin/Hydrochlorothiazid Glenmark is used for managing high blood pressure through several complementary mechanisms.

• Hypertension: lowers systolic and diastolic blood pressure when monotherapy is insufficient.
• Hypertension with fluid retention: adds diuretic effect to improve control.
• Hypertension in patients requiring calcium‑channel blockade: provides vasodilation alongside renin‑angiotensin inhibition.
• Hypertension resistant to single‑agent therapy: offers triple‑component synergy for better target achievement.
• Hypertension in elderly patients: simplifies regimen with once‑daily dosing.
• Hypertension with metabolic considerations: allows dose titration of each component as needed.

• The combination works by three complementary actions: olmesartan blocks the angiotensin II type 1 receptor, preventing vasoconstriction; amlodipine inhibits calcium influx into vascular smooth‑muscle cells, causing arterial dilation; and hydrochlorothiazide reduces sodium and water reabsorption in the distal convoluted tubule, decreasing plasma volume. Together these effects lower systemic vascular resistance and cardiac output, producing an overall antihypertensive response.

Common Side Effects

• Headache: mild to moderate headache may occur.
• Peripheral edema: swelling of ankles or feet is frequently reported.
• Dizziness: especially after the first doses or rapid posture changes.
• Fatigue: a general feeling of tiredness can be experienced.
• Flushing: transient warmth or redness of the skin.
• Cough: occasional dry cough, more typical of angiotensin‑blocking agents.

Serious or Rare Side Effects

• Hyperkalemia: elevated potassium levels requiring monitoring.
• Acute kidney injury: sudden decline in renal function.
• Severe hypotension: marked drop in blood pressure leading to fainting.
• Hepatic dysfunction: abnormal liver enzymes or hepatitis.
• Angio‑edema: swelling of face, lips, tongue or airway.
• Blood dyscrasias: rare blood‑cell abnormalities such as agranulocytosis.

Olmesartan/Amlodipin/Hydrochlorothiazid Glenmark should be used with caution in specific clinical situations.

• Renal impairment: monitor kidney function and electrolytes regularly.
• Hepatic disease: dose adjustment may be required; watch for liver enzyme changes.
• Electrolyte imbalance: especially potassium and sodium levels need periodic checks.
• Pregnancy: avoid use; drug is contraindicated in the first trimester and beyond.
• Elderly patients: start at lower dose and assess tolerance.
• Drug‑induced photosensitivity: advise patients to use sun protection.
• Store at ambient temperature: keep below 25°C, protect from moisture and light.

Olmesartan/Amlodipin/Hydrochlorothiazid Glenmark may interact with several medicines.

Major Interactions (Avoid)

• Potassium‑rich supplements or salts: risk of hyper‑kalemia.
• Strong CYP3A4 inhibitors (e.g., ketoconazole): increase amlodipine levels.
• NSAIDs (high dose): may blunt antihypertensive effect and affect renal function.

Moderate Interactions (Monitor Closely)

• Lithium: may increase lithium concentrations.
• Diuretics other than hydrochlorothiazide: additive electrolyte disturbances.
• ACE inhibitors or ARBs: risk of excessive potassium loss and renal impairment.